MMP9 and neoplasm: Combining TCR‐T therapy with enhanced co‐stimulatory molecules, such as adhesion and accessory molecules, or modifying the tumour microenvironment (e.g., using MMP9 inhibitors), could potentially improve therapeutic efficacy [66, 69].